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Purpose: There are increased levels of nitric oxide (NO) in diabetic retinas. The purpose of this study was to determine
the extent that neuronal nitric oxide synthase (nNOS) contributes to the increased levels of retinal NO in early diabetic
retinopathy by examining the expression and activity of nNOS in retinal neurons after 5 weeks of diabetes.
Methods: Changes in NO levels were measured using NO imaging of retinal neurons in mice with streptozotocin-induced
diabetes for five weeks. NO imaging was compared to nNOS localization using immunocytochemistry, and nNOS message
and protein levels were measured using quantitative real-time PCR and western blots.
Results: There was a close anatomic correlation between the localization of the increased NO production and the nNOS
immunoreactivity in the retinal plexiform layers of diabetic retinas. There was no change in nNOS message, but nNOS
protein was decreased and its subcellular localization was altered. Treatment with insulin or aminoguanidine partially
ameliorated the increase in NO in diabetic retinas.
Conclusions: These results suggest that increased nNOS activity is responsible for the majority of increased NO in retinal
neurons in early diabetic retinopathy. This supports a role for increased nNOS activity in the early neuronal dysfunction
in the diabetic retina.
Diabetic retinopathy (DR) is one of the leading causes of
blindness among working age adults in the developed world
[1]. DR is characterized by both neuronal dysfunction and the
breakdown of the retinal vasculature [2]. Complications in the
vasculature are important for disease progression and are easy
to detect clinically. As a consequence, many studies have
approached DR as being primarily vascular in its etiology.
However, retinal neuron dysfunction occurs early in DR and
may even precede vascular breakdown [3,4].
Evidence of early neuronal dysfunction is demonstrated
as aberrant electroretinogram (ERG) responses before any
visible vascular damage in diabetic rats [4,5] and humans [6,
7]. Shirao and Kawasaki [8] concluded that the oscillatory
potentials (OP) were the first ERG components affected in
diabetes. OP changes are a better predictor of DR in humans
than  fundus  photography  or  fluorescein  angiograms  [9].
Evidence for changes in visual processing has been seen in as
little as two weeks in diabetic rats [10], while discernable
vascular changes have been noted to occur after six months to
one year [11]. Similarly, there is a decrease in color and
contrast sensitivity and aberrant ERGs in diabetic humans
after two years [12-14], while major vascular changes do not
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typically occur until 5–10 years after the onset of diabetes
[3].
Several  neurochemical  changes  have  also  been
documented early in the diabetic retina. For example, Leith et
al. [15] found increased glial fibrillary acidic protein (GFAP)
in Müller cells along with increased levels of glutamate and
an impaired breakdown of glutamate to glutamine. There is
an increase in retinal neuron apoptosis early in DR, which also
precedes the vascular damage in both rodents and humans
[16,17]. The presynaptic proteins synaptophysin, synapsin 1,
VAMP2, SNAP25, and PSD95 all show decreases after only
one  month  of  diabetes,  especially  when  synaptosomal
fractions are selectively examined [18]. A study by Kern et al.
[19] showed that early vascular damage was prevented in rats
by administering the COX inhibitor, nepafenac, but retinal
ganglion cell apoptosis still occurred, denoting a separation
between vascular and neuronal damage.
Nitric oxide (NO) is an important signaling molecule in
the vertebrate retina found to either be produced by or have
effects in every retinal cell type [20]. There is evidence for
increased NO in both the vitreous and aqueous humors of
patients with DR [21,22]. We have previously shown that
neuronal nitric oxide synthase (nNOS) is the primary source
of neuronal NO and the most abundant form of nitric oxide
synthase (NOS) in retina [23-25]. However, there is little
characterization of nNOS in DR, and the results have been
inconsistent [26,27].
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2249In this study, we examined changes in NO and nNOS in
the retinas of mice that had streptozotocin-induced diabetes
(STZID)  for  five  weeks.  We  found  no  change  in  nNOS
message levels, but nNOS protein levels decreased and its
subcellular localization was altered in the inner plexiform
layer (IPL). Despite this, total NO levels quantified using the
NO-sensitive  dye  diamino-5-methylamino-2',7’-
difluorofluorescein  diacetate-FM  (DAF-FM)  increased
significantly.  The  increased  NO  production  was  closely
anatomically  correlated  with  the  immunocytochemical
localization of nNOS. The results of this study suggest that
nNOS enzyme activity is upregulated early in DR and is
concomitant with neuronal dysfunction.
METHODS
Unless specified otherwise, all reagents were purchased from
Sigma (St. Louis, MO) or Fisher Scientific (Waltham, MA).
All of the experiments were done in normal room light, with
the exception of the NO imaging, which, for technical reasons,
was  done  using  dark-adapted  retinas.  All  statistical
evaluations  were  performed  using  OriginPro  8  software
(OriginLab, North Hampton, MA).
Animals: Adult (between 3 and 5 months of age), male
C57BL/6  mice  were  purchased  from  Charles  River
Laboratories (Wilmington, MA) and were kept on a standard
12 h:12 h light-dark cycle with free access to food and water.
All animals were treated using protocols approved by the
Boston  University  Charles  River  Campus  Institutional
Animal Care and Use Committee. Mice were age matched and
made diabetic by an intraperitoneal (IP) injection of 75 mg/kg
streptozotocin (STZ; Alexis Biochemicals, San Diego, CA) in
pH 4.5 citrate buffer; each injection was given after an 8-h
fast, one injection per day for three consecutive days. Control
animals received three IP injections of citrate buffer alone
after an 8 h fast on the same days as the experimental animals.
The animals were allowed to recover for two days before their
blood glucose levels were tested with a FreeStyle FlashTM
blood glucose meter (Therasense, Almeda, CA). Mice were
considered diabetic if their fasting blood glucose level was at
or over 250 mg/dl. Animals that did not become diabetic were
not  used  for  this  study.  Treatment  with  insulin,
aminoguanidine (AG), or Nω-nitro-L-arginine methyl ester
(L-NAME) was given to subsets of animals starting one week
after induction of diabetes. Thus, these treatments were given
for a duration of 4 weeks up to the time of sacrifice as follows.
Once a day, 2 U/kg insulin from bovine pancreas (in sterile
saline; Sigma I5500) was administered via IP injection. Also
once a day, NOS inhibitor L-NAME (37.5 mg/kg in sterile 0.1
M pH 7.4 phosphate buffer, PB) was administered by IP.
Every day, 1 g/l AG, an inhibitor of both NOS and advanced
glycation end product (AGE) formation, was administered to
animals in their drinking water, which was changed daily.
Animal weight and fasting blood glucose levels were recorded
at the beginning and end of each experimental cycle. Final
blood  glucose  levels  and  bodyweights  were  compared
between each group using ANOVA. Post hoc analysis was
performed  using  Tukey’s  test.  A  p<0.05  was  considered
significant. Animals were euthanized in each experiment by
exposing  them  to  IsoFlow™  Isoflurane  gas  (Abbott
Laboratories) until they were deeply anesthetized, and then
they were immediately decapitated.
Protein  extraction  and  western  blotting:  Following
sacrifice,  the  eyes  were  rapidly  removed  and  placed  into
balanced salt solution (BSS; 137 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 15 mM D-glucose, 1 mM MgSO4, 1 mM Na2HPO4, and
10mM HEPES, pH 7.4) and the retinas were then surgically
isolated  from  the  eyes.  Specimens  in  solution  were
immediately placed into 1.5 ml centrifuge tubes, set on dry
ice. Six retinas (three animals) were pooled together to ensure
an  adequate  amount  of  protein  for  detection  by  western
blotting.  The  retinas  were  then  suspended  in  200  μl  of
homogenization buffer containing 20 mM Tris-HCl, 0.05%
SDS, and 1X Complete Mini Protease Inhibitor Cocktail with
EDTA  (Roche  Applied  Science,  Indianapolis,  IN)  before
being ultrasonically homogenized. The protein concentration
in each sample was determined using the Bradford method. In
each lane, 100 μg protein was loaded onto 8% SDS PAGE
gels  and  transferred  onto  0.4  μm  Immobilon™  PVDF
membranes  (Millipore,  Billerica,  MA).  A  rapid  detection
method was used, whereby the blocking step was omitted
[28]. The primary antiserum was a rabbit anti-nNOS (sc648;
Santa Cruz Biotechnology, Santa Cruz, CA) that was diluted
1:5,000  in  2%  BSA  in  Tris  buffered  saline  w/  0.25%
Tween-20 (TBST). The secondary antibody was a horseradish
peroxidase-conjugated  goat  polyclonal  antiserum  raised
against rabbit IgG (Molecular Probes, Invitrogen, Carlsbad,
CA) at a dilution of 1:100,000. The blots were then treated
with Immobilon™ HRP substrate (Millipore) and exposed to
blue X-ray film (F-BX57; Phenix, Asheville, NC). To confirm
equal lane loading, we stripped the blots and reprobed them
with  mouse  anti-β-tubulin.  The  β-tubulin  monoclonal
antibody used was developed by Dr. Willi Hafler and was
obtained from the Developmental Studies Hybridoma Bank.
This  antibody  was  developed  under  the  auspices  of  the
NICHD  and  is  maintained  by  The  University  of  Iowa
(Department of Biology, Iowa City, IA). Quantitative analysis
was performed using Image J image analysis software (Wayne
Rasband, National Institute of Mental Health, Bethesda, MD).
The difference in protein levels was evaluated using the paired
Student’s t-test. A p<0.05 was considered significant.
Immunocytochemistry: After euthanasia, the mouse eyes
were  rapidly  enucleated  and  placed  in  ice-cold  BSS.  The
anterior chamber, lens, and vitreous were then removed and
the  resultant  eyecups  were  immediately  placed  into  4%
paraformaldehyde in PB for 90 min at room temperature.
Next, the eyecups were cryoprotected in 30% sucrose in PB,
embedded  and  frozen  in  Optimal  Cutting  Temperature
embedding media (OCT; Tissue-Tek, Miles, Inc., Elkhard,
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and mounted on Superfrost /Plus® slides (Fisher Scientific).
The  eyecups  from  the  control  and  diabetic  mice  were
embedded into the same block and cryosectioned onto the
same slide to reduce variability when comparing changes in
immunoreactivity.  The  asymmetry  provided  by  this
embedding method allowed us to clearly distinguish each of
the  eyecups  in  the  resultant  cryosections.  Thus  we  could
embedded one eye from each of 4 separate mice with different
treatments in the same block.
Immunocytochemistry  was  performed  on  the  retinal
sections  using  standard  methods  as  previously  described
[25,29]  on  retinal  cross-sections  mounted  on  slides.
Immunochemical procedures were replicated, using at least
three different animals (n=3), where each "n" was the average
of three trials for a given animal compared to the other retinas
on the same slide as described in the previous paragraph. The
primary antiserum used was rabbit anti-nNOS (sc648; Santa
Cruz Biotechnology) at a dilution of 1:1,000 overnight in a
humid chamber at 4 °C. The slides were then washed 3×10
min in 0.1 M PB at room temperature and then incubated for
2 h in an Alexa488-conjugated goat anti-rabbit IgG secondary
antiserum (Molecular Probes, Carlsbad, CA) at a dilution of
1:500. Incubation with the primary antiserum omitted served
as a control for nonspecific secondary antiserum staining.
Slides were washed in 0.1 M PB as before, coverslipped with
glycerol, and the fluorescent signal was visualized using an
Olympus Fluoview™ 300 confocal microscope (Olympus,
Melville, NY). The excitation was done using the 488 nm laser
line from an argon laser and the emission was visualized using
a 510–550 nm bandpass filter. Ten to 14 optical sections were
taken at 1 μm intervals, with the same number of optical
sections always being captured and compared for both the
control and experimental retinas. The laser intensity and all
confocal settings were kept consistent within replicates.
The  “z  project”  function  of  Image  J  image  analysis
software was used to obtain a single image from a collapsed
confocal optical stack. The images were then converted to
inverted grayscale so that the immunoreactivity would appear
black. Mean intensity values were then recorded for each
treatment and compared to the control retina on the same slide.
These values were averaged together for each animal and
compared  to  the  average  control  mean  using  the  paired
Student’s t-test. A p<0.05 was considered significant. The
relative  intensity  of  immunoreactivity  within  each  retinal
layer was quantified using Image J to produce a horizontal
line-profile average of the intensity of the immunoreactivity
in the different retinal layers, minimizing the effect of local
regional differences.
RNA  isolation  and  reverse  transcription:  The  retinas
were  isolated  in  BSS  as  described  in  the
immunocytochemistry methods section, although all reagents
and materials were kept RNase-free. Total RNA was then
isolated from the retinas using a standard Trizol™ reagent
(Invitrogen, Carlsbad, CA) extraction. To obtain sufficient
amounts of RNA to perform these reactions, we pooled three
animals (six retinas) together for each extraction. The RNA
was  then  treated  with  rDNase™  (Ambion,  Applied
Biosystems,  Austin,  TX),  following  the  manufacturer’s
instructions, to remove any DNA contaminants. The RNA
was  quantified  using  a  Nanodrop™  spectrophotometer
(ThermoFisher  Scientific,  Waltham,  MA).  RNA  was  then
converted  into  cDNA  using  the  Verso™  cDNA  kit
(ThermoFisher Scientific) and subsequently treated with 2 U
of RNase H™ (ThermoFisher Scientific) at 37 °C for 20 min.
Quantitative real-time PCR analysis: Quantitative real-
time  PCR  analysis  (qPCR)  was  performed  using  cDNA
converted  from  1  µg  of  retinal  RNA  as  described  in  the
previous section, using an ABI PrismTM 7900HT Sequence
Detection System (Applied Biosystems, Carlsbad, CA). We
used  a  pre-designed  TaqMan™  gene  expression  assay
(Applied  Biosystems)  for  nNOS  (assay  ID:
Mm00435173_m1).  Our  normalizing  control  was  an
optimized 18s rRNA primer set that was kindly provided to
us by Dr. Ulla Hansen (Boston University, Boston, MA),
which was designed to work with SYBR Green™ (Applied
Biosystems).  All  data  was  obtained  in  quadruplicate  and
analyzed using the Microsoft ExcelTM qGene template [30].
NO imaging: NO imaging was performed as reported
previously [24]. Since DAF-FM is a light sensitive dye, all
aspects of the NO imaging experiments, beginning with the
retinal eyecups, were done in the dark using infrared imaging,
except for the actual final light stimulations. To prepare retinal
slices,  we  enucleated  the  eyes  and  removed  the  anterior
segment of the eye and lens under dim light. We placed the
eyecups  in  chilled  aerated  artificial  cerebrospinal  fluid
(ACSF, 125 mM NaCl, 26 mM NaHCO3, 3 mM KCl, 1.6 mM
CaCl2, 1.5 mM MgSO4, 1.25 mM NaH2PO4, and 10 mM
glucose) in the dark on ice for 1 h to allow the retinas to recover
and fully dark adapt. The eyecups were then sectioned into
250-µm-thick slices. Loading of the NO-sensitive dye, DAF-
FM (Molecular Probes), was done as previously described
[31]. Briefly, slices were allowed to recover from slicing for
at  least  30  min  in  ACSF  at  room  temperature  and  then
incubated for 60 min in ACSF containing 10 µM of DAF-FM
at 37 °C. Slices were then washed 3x 15 min with fresh,
aerated ACSF at 37 °C.
Some  slices  were  stimulated  for  20  min  with  a  light
emitting diode (660 nm, 3Hz, 20 µW, 25% duty cycle), while
a matched set of slices were kept in the dark for comparison.
Light-stimulated and control sections were then fixed in the
dark for 2 h with 4% paraformaldehyde in PB and then they
were washed 4×15 min in 0.1 M PB at room temperature.
Fluorescent images of the retinal slices were acquired using a
FluoviewTM 300 confocal microscope (Olympus Corporation)
using a 40× water immersion objective and the FluoviewTM
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using Image J software as described above.
To  ensure  unbiased  thresholding  of  the  images  when
comparing  the  different  retinal  regions  or  treatments,  we
assigned a threshold value, using a custom written Image J
plugin, which determined the inflection point for the region
of interest (ROI) of each collapsed confocal optical image
stack. Briefly, on a plot of arbitrary fluorescent units obtained
from the confocal microscope versus the number of pixels in
the image, the inflection point was computed as a point on the
curve at which the tangent crossed the curve. Fluorescent
pixels above this threshold value were quantified for each ROI
using the “ROI manager.”
The quantitative analysis of these collapsed image stacks
was done using the freehand selection tool in Image J to select
specific ROIs. At least 25 ROIs from each animal in each
category and at least five animals in each treatment group were
analyzed in this manner. The average number of fluorescent
pixels of all images from one animal was considered as n=1.
The final graphs depict the mean and standard deviation (SD)
of at least n=5 animals to average out any minor local intensity
differences.  The  difference  between  the  control  and
experimental groups was analyzed using ANOVA. Post hoc
analysis was performed using Tukey’s test. A p<0.05 was
considered significant.
RESULTS
General condition of the mice used in this study: Mice with
STZID averaged a lower weight when compared to controls
after five weeks, however this difference was not statistically
significant  (Table  1).  The  only  statistically  significant
differences were between control and insulin (p=0.0004) and
control  and  L-NAME  (p=0.03).  To  our  observation,  the
diabetic mice had slightly diminished body appearance and
activity levels; their activity levels were returned to normal by
administering  insulin  or  AG.  In  addition  to  diminished
bodyweight, the animals that received L-NAME appeared
more emaciated and lethargic than their untreated diabetic
counterparts (data not shown).
Blood  glucose  levels  were  significantly  elevated  in
diabetes (p<0.0001). These levels were significantly lowered
by  insulin,  although  it  was  still  significantly  higher  than
control (p<0.0001). L-NAME or AG did not appear to affect
blood glucose levels and were not significantly different from
untreated diabetic, but remained significantly different from
control and insulin treated animals (p<0.0001; Table 1).
NO increased after 5 weeks of STZID and was reduced by
insulin,  aminoguanidine,  or  L-NAME:  To  examine  any
changes in NO levels in the retina after 5 weeks of STZID, we
measured the NO-induced fluorescence (NO-IF) using the NO
sensitive dye DAF-FM. We detected basal levels of NO-IF in
all retinal layers in the dark-adapted retinas (Figure 1A). We
observed  an  overall  increase  in  NO-IF  in  dark-adapted
diabetic retinas. In comparison to control retinas, the intensity
of NO-IF in diabetic retinas increased significantly in the outer
plexiform layer (OPL) by 82±19% (p<0.0001) and in the IPL
by 48±18% (p=0.016; Figure 1A,B). NO-IF also appeared in
the diabetic outer nuclear layer (ONL), which was usually not
seen  in  the  control  ONL  (Figure  1A).  Interestingly,
presumptive bipolar cells in the control inner nuclear layer
(INL) often had NO-IF both in their somata and processes, but
they appeared to have lost NO-IF in their processes in the
diabetic condition. There was no significant change in the
number  or  intensity  of  labeled  cell  bodies  in  the  INL  or
ganglion cell layer (GCL) in diabetic retinas when compared
to controls.
Treatment with insulin partially reduced the NO-IF in the
diabetic retinas (Figure 1A,B). Insulin treatment lowered NO-
IF levels in the OPL and IPL to about half that of the untreated
diabetics, however this trend was only statistically significant
in the OPL (p=0.01). Neither the number of cells exhibiting
NO-IF nor the intensity of NO-IF in the INL and GCL were
significantly  different  from  controls.  In  addition,  insulin
TABLE 1. HEALTH CHARACTERISTICS OF MICE USED IN THIS STUDY.
Experimental group Weight (g) Blood glucose (mg/dl)
Control 26±0.3 129±14
Diabetic 22±1 486±9
Insulin 17±2 264±14
L-NAME 21±1.8 454±23
AG 22±0.8 433±22
Mice with streptozotocin-induced diabetes (STZID) had lower weights when compared to controls after 5 weeks, but the
difference was not statistically significant. The differences in weight between control and insulin treatment (p=0.0004) and
control and Nω-nitro-L-arginine methyl ester (L-NAME; p=0.03) were significant. Blood glucose levels were significantly
elevated in diabetes (p<0.0001) and this was significantly lowered by insulin, although it was still significantly higher than
control (p<0.0001). L-NAME or aminoguanidine (AG) did not appear to affect blood glucose levels and were not significantly
different from untreated diabetic. Values are presented±SEM.
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2252restored NO-IF to some processes of somata in the INL and
greatly decreased the levels of NO-IF in the ONL (Figure 1A).
While insulin did help restore NO-IF to near normal levels,
we did not observe a complete rescue. This was most likely
because the insulin was only administered once daily. As a
consequence, the blood glucose levels of the insulin treated
mice were lower than the untreated diabetics, although their
blood  glucose  levels  were  still  elevated  above  250  mg/dl
(Table 1).
Treatment with L-NAME reduced retinal NO-IF to levels
too low to be detected by our NO imaging method (data not
shown). Treatment with AG significantly returned NO-IF to
near control levels in the OPL (86±14%, p<0.0001) and in the
IPL (80±18%, p=0.004; Figure 1B), but the NO-IF in the
processes in the INL did not return with AG treatment as it
Figure 1. Changes in NO-induced fluorescence (NO-IF) in the diabetic retina. A: NO-IF increased in the diabetic retina compared to control.
NO-IF in processes from somata in the inner nuclear layer (INL) were present in control (white arrowhead) but absent in the diabetic. Treatment
with insulin or aminoguanidine (AG) reduced NO-IF and insulin restored NO-IF in some the processes in the INL (white arrowheads). Scale
bars represent 25 μm. Quantitative analysis of NO-IF in retinal regions is shown in dark-adapted unstimulated (B) and light-stimulated retinas
(C) as compared to control (100%). The outer and inner plexiform layers (OPL and IPL) depict the percent intensity, while the inner nuclear
layer (INL) and ganglion cell layer (GCL) depict the percent of NO-IF labeled somata. B, C: Like symbols indicate statistically significant
differences between groups (* represents diabetic versus control OPL, # represents diabetes versus control IPL; p<0.05). Error bars represent
SD.
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NO-IF and intensity in the INL and GCL levels were not
significantly different from control.
While  the  results  described  were  for  dark-adapted,
unstimulated retinas, we also performed the same experiments
using retinas stimulated with flashing light (Figure 1C). The
results were comparable to retinas in the dark, although the
basal  levels  of  NO-IF  were  higher  in  stimulated  control
retinas. In diabetic mice, the NO-IF in the OPL significantly
increased by 49 ± 11% (p=0.0002), while in the IPL it went
up by 23±13% (p=0.02). Interestingly, insulin seemed to have
a  stronger  effect  in  the  OPL  and  IPL  of  light-stimulated
retinas, significantly lowering NO-IF to near control levels in
the  OPL  (93±18%,  p<0.0001)  and  in  IPL  (83±17%,
p=0.0016). AG had a dramatic effect in the light-stimulated
retinas, with intensities significantly down to 112±13% in the
OPL (p=0.02) and lower (but not statistically significant) to
98±14% in the IPL (Figure 1B,C).
nNOS protein levels decrease after 5 weeks of STZID: While
NO-IF increased, nNOS-like immunoreactivity (nNOS-LI)
significantly decreased by 21±11% in the OPL (p=0.005),
15±9% in the IPL (p=0.012), 19±17% in the INL (p=0.001),
and 26±14% in the GCL (p=0.006; Figure 2A). These changes
were not affected by treatment with insulin or AG (data not
shown). There was nNOS-LI in the IPL in many apparent
neuronal processes in control retinas. Interestingly, nNOS-LI
was largely absent from such processes of the IPL in the
diabetic condition and appeared more punctate in expression,
suggesting nNOS-LI was in synaptic boutons (Figure 2B).
Western blots probed with the nNOS antiserum confirmed an
overall reduction of nNOS protein by 24±11% (p=0.005),
consistent  with  our  immunocytochemistry  (ICC)  findings
(Figure 2C).
To determine if the change in nNOS protein was due to
a decrease in nNOS gene expression, we performed qPCR
using an Applied Biosystem’s TaqMan™ assay. We found no
difference in nNOS mRNA expression levels between control
and diabetic retinas (Figure 3), an indication that changes in
nNOS protein levels were not due to changes in its gene
expression.
DISCUSSION
Neuronal versus vascular complications: Several studies of
DR find evidence for cellular and metabolic abnormalities in
retinal neurons before vascular complications [4,8,32]. In both
human and animal models of DR, retinal dysfunction can first
be detected using ERGs, long before any vascular pathology
becomes apparent [8]. However, permeability changes can
occur as early as eight days after diabetic onset in rats [33],
and future studies should consider this. Nonetheless, studies
that have looked at the vasculature in greater detail did not
find major vascular complications until 6 months to 21 months
after the onset of diabetes in rodents [11,32,34,35].
Role  of  nNOS  in  diabetic  retinopathy:  We  found  a  large
increase  in  NO  production,  which  mirrored  the  anatomic
localization of nNOS-LI, despite an overall decrease in nNOS
protein  levels.  There  have  been  relatively  few  studies
examining nNOS in retinal neurons of diabetic animals, and
the results have varied. One study used a combination of
western blots and ICC to conclude that the number of nNOS-
positive bipolar cells increases in the INL of the diabetic rat
after nine weeks [26]. More consistent with our findings, an
Figure 2. nNOS protein levels decreased after 5 weeks of diabetes. A: Mean fluorescence levels of nNOS immunoreactivity were significantly
reduced in the outerplexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer (IPL), and ganglion cell layer (GCL) when
compared to controls (n=11). The graph on the right indicates the line profile average of the intensity of nNOS in each layer of the retina. B:
nNOS immunoreactivity in the IPL no longer filled neuronal processes in the diabetic and was localized in structures which resembled synaptic
boutons in size and location. C: western blots detected a single ~160 kDa band consistent with nNOS. Levels of β-tubulin are shown to confirm
equal protein loading. There was a 24%±11 decrease in total nNOS protein (C is control, D is diabetic; n=8). Line on the left indicates the
location of the 150 kDa molecular weight marker.
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histochemistry and ICC found that the total number of nNOS
expressing neurons decreases, and this loss is prevented by
AG [27].
nNOS is responsible for the increases in NO-IF in the OPL
and IPL: It is theoretically possible that some of the NO-IF
we observed was produced from inducible NOS (iNOS) or
endothelial  NOS  (eNOS).  Several  studies  have  examined
iNOS as a potential mediator of DR. However, these studies
all indicated that iNOS plays a critical role in subsequent
vascular damage and do not link iNOS with early neuronal
dysfunction [36-38]. Du et al. [39], showed that high glucose
caused an increase in iNOS in the Müller cell culture line
rMC-1, but not in bovine retinal endothelial cells. Abu El-
Asrar et al. [38] detect iNOS in Müller cells of human patients
with  DR,  but  not  in  any  cells  of  the  retinas  of  normal
individuals. Therefore, although iNOS is clearly involved in
the  pathology  of  the  diabetic  retina,  it  is  more  closely
associated  with  glial  and  vascular  complications.  To  our
knowledge, there is no definitive evidence linking iNOS to
the early neuronal pathology seen in DR, and there has been
no selective localization of iNOS within the IPL or OPL. In
contrast,  our  NO  imaging  results  from  this  and  previous
studies [24,25] clearly indicated that the NO-IF in retina is
closely anatomically correlated with nNOS-LI—observations
that support our belief that the increased NO was coming from
nNOS and not iNOS.
Although we detected relative low levels of eNOS mRNA
compared to nNOS mRNA in retina using qPCR and found
eNOS-LI in retinal vasculature (data not shown), we did not
detect eNOS in retinal neurons using several commercially
available  eNOS  antisera  (Santa  Cruz  Biotechnology,  Inc.,
sc8311, sc653, and sc654; BD Transduction Labs, 610298).
However, this was not surprising since previous work shows
only weak immunocytochemical staining of eNOS protein in
the INL and blood vessels, suggesting that it is not abundant
in the retina [36,40]. Although there is evidence that eNOS is
involved in vascular complications of DR, the vasculature
only makes up about 3%–5% of the retina [36,41]. Most
important, the increased NO-IF we observed in the plexiform
layers is not likely to be produced by eNOS, because the NO-
IF is clearly not associated with blood vessels.
If NO is contributing to various stages of DR, then it is
extremely  important  to  find  usable  inhibitors  of  NOS  as
potential therapeutic targets. Gross inhibition of NOS is not a
realistic option, as we found that L-NAME almost completely
eliminated NO-IF and this treatment was not well tolerated.
In  the  present  study,  AG  was  well  tolerated,  and  it  was
apparent that AG was able to inhibit nNOS. Other studies also
show that AG is not exclusively an iNOS inhibitor, as it is
often reported to be [42,43]. However, since AG is also an
inhibitor of AGE formation [44,45], we cannot discount the
role AGE formation may play in regulating NO levels.
Potential mechanisms for increased nNOS activity: In both
diabetic human [46] and rat retinas [47], there is increased
NMDA  receptor  NR1  subunit  immunoreactivity.  These
NMDA  receptor  channels  provide  an  important  route  for
Ca2+  entry,  and  subsequent  activation  of  Ca2+-dependent
intracellular  enzymes  such  as  nNOS.  Neurotoxicity
associated  with  excitatory  amino  acids  is  reported  to  be
mediated to a large extent through the activation of NMDA
receptors [48]. Since nNOS activity is Ca2+-dependent and
calmodulin-dependent, it would be also be activated by these
Ca2+ increases [49]. Furthermore, a subset of nNOS resides at
the post-synaptic density by virtue of its PDZ-domain; this
may explain why the nNOS we find remaining in the diabetic
IPL appears largely synaptic [50]. Any nNOS at the post-
synaptic density would be in close proximity to the largest
influxes of calcium. Thus the reduction of nNOS protein may
be compensated for by large glutamate-induced influxes of
calcium at synapses.
Another significant possibility is that there is a post-
translational activation of nNOS. nNOS enzyme activity is
strongly  inhibited  by  a  Ca2+-dependent  and  calmodulin-
dependent  protein  kinase  II  that  phosphorylates  nNOS  at
Figure 3. qPCR measurements of retinal nNOS transcripts using an
Applied  Biosystems  TaqMan™  assay.  No  difference  was  seen
between control and diabetic nNOS mRNA levels. The values are
depicted as mean normalized expression (MNE) compared to the 18s
rRNA (n=4). The data were analyzed using the qGene template
[30], using the following equation:
where; Etarget, PCR amplification efficiency of the target gene; Eref,
PCR  amplification  efficiency  of  the  reference  gene;  CTtarget,
threshold cycle of the PCR amplification of the target gene; CTref,
threshold cycle of the PCR amplification of the reference gene. The
CT  was  defined  as  the  cycle  at  which  the  fluorescence  rises
appreciably  above  the  background  fluorescence  and  determined
automatically using Applied Biosystems SDS software version 2.3.
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4Ser847 [51,52]. Increased levels of Ca2+ can activate calcineurin
(PP2B) to dephosphorylate nNOS at Ser847, which in turn
allows  nNOS  to  increase  NO  production  [53].  Thus  it  is
possible  that  increased  Ca2+  levels  can  stimulate  NO
production in two distinct ways: by increasing intracellular
Ca2+ to directly activate nNOS, and by activating calcineurin
to activate nNOS through dephosphorylation of an inhibitory
site.
Consequences of increased NO production in diabetes: There
are several potential molecular and cellular consequences of
an increase in NO in synapses. One consequence of diabetes
is hypoxia in the diabetic retina [54]; NO from nNOS has been
shown  to  sensitize  neurons  to  hypoxia-induced  death  via
competitive inhibition of cytochrome oxidase [55]. Thus, the
increased NO may contribute to the early neuronal cell death
in  DR.  NO  has  also  been  shown  to  increase  release  of
neurotransmitters  through  both  cGMP-dependent
mechanisms [56] and through Ca2+ independent mechanisms
involving synaptic vesicle docking and fusion reactions [57].
In  particular,  NO  has  been  shown  to  increase  release  of
glutamate in chick retina [58]. In contrast, NO has been shown
to  decrease  glycine  release  in  retina  [59].  Such  increased
levels of retinal glutamate and decreased release of glycine
may also be related to the increased cell death in DR. These
neurochemical changes are consistent with studies using a
combination of ICC, western blots, and qPCR that report that
the presynaptic proteins synaptophysin, synapsin 1, VAMP2,
SNAP25, and PSD95 all showed decreases after only one
month of diabetes, especially when synaptosomal fractions
were selectively examined [18].
Future  studies  will  need  to  determine  the  exact
mechanisms that led to the increase in nNOS activity. In
addition, it will be important to separate the timing and relative
contributions of nNOS versus iNOS to get an accurate picture
of how each pool of NO affects the retina as a whole. However,
the results of our study indicate that nNOS may play a major
role in providing excess NO in early DR. Future studies should
address  how  this  pathologically  increased  NO  can  be
selectively reduced without detrimentally affecting the many
normal functions of NO in the retina. This approach could
provide  a  significant  new  strategy  for  treating  the  early
neuronal cell loss in DR.
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